What Is DNA Methylation

DNA methylation is a biochemical process in which a methyl group (one carbon atom bonded to three hydrogen atoms) is added to a cytosine base in DNA, most commonly at CpG dinucleotide sites. This chemical tag does not change the DNA sequence itself but alters whether a gene is read or silenced by the cell's transcription machinery. Methylation patterns vary by tissue type, change over time, and respond to environmental exposures, making them a central mechanism of epigenetic regulation.

DNA methylation sits at the intersection of genetics and environment, acting as a layer of information that determines which genes are active in a given cell at a given time. Because methylation patterns shift in predictable ways as organisms age, they have become one of the most studied biomarkers of biological aging. Epigenetic clocks built from methylation data can estimate a person's biological age independently of their chronological age, and the gap between these two numbers correlates with disease risk and mortality.

For longevity, methylation matters on two levels. First, the progressive disregulation of methylation across the genome contributes to the functional decline seen in aging: tumor suppressor genes may become silenced, inflammatory genes may become inappropriately activated, and cellular identity can erode. Second, methylation is modifiable. Unlike the DNA sequence, which is fixed at conception, methylation patterns respond to nutrition, exercise, toxin exposure, and other lifestyle factors. This makes methylation both a readout of how well the body is aging and a potential target for interventions.

The biochemistry of DNA methylation centers on the transfer of a methyl group from S-adenosylmethionine (SAM) to the fifth carbon of a cytosine base, producing 5-methylcytosine (5mC). This reaction is catalyzed by a family of enzymes called DNA methyltransferases (DNMTs). DNMT1 is primarily responsible for maintaining existing methylation patterns during cell division, copying the methylation marks from the parent strand to the newly synthesized daughter strand. DNMT3a and DNMT3b establish new (de novo) methylation marks during development and in response to signals throughout life.

Methylation typically represses gene expression when it occurs at promoter regions, the stretches of DNA upstream of a gene where transcription factors bind. A heavily methylated promoter attracts methyl-CpG-binding domain proteins, which recruit histone-modifying complexes that compact the surrounding chromatin and make the gene physically inaccessible. Conversely, demethylation can reactivate silenced genes. Active demethylation involves TET (ten-eleven translocation) enzymes that oxidize 5-methylcytosine through a series of intermediates (5-hydroxymethylcytosine, 5-formylcytosine, and 5-carboxylcytosine) before the modified base is excised and replaced by an unmodified cytosine through base excision repair.

The methylation cycle that supplies SAM connects directly to one-carbon metabolism, a network of folate-dependent reactions that also involves vitamins B12, B6, and the amino acid methionine. Methionine is adenylated to form SAM; after donating its methyl group, SAM becomes S-adenosylhomocysteine and then homocysteine, which must be remethylated (using folate and B12) or transsulfurated (using B6) to prevent toxic accumulation. This metabolic architecture means that nutritional status, genetic variants in enzymes like MTHFR, and other metabolic inputs all feed into the cell's capacity to maintain proper methylation.

DNA methylation is one of the most extensively studied epigenetic modifications, with thousands of published studies spanning developmental biology, oncology, and aging. The development of epigenetic clocks represents a major contribution: the original Horvath clock, published in 2013, demonstrated that methylation at 353 CpG sites could predict chronological age across multiple tissues with notable accuracy. Subsequent clocks, particularly GrimAge and DunedinPACE, have been refined to predict not just age but mortality risk and pace of aging, respectively. Large epidemiological studies have confirmed that accelerated epigenetic aging (biological age exceeding chronological age) associates with higher all-cause mortality, cardiovascular disease, cancer incidence, and cognitive decline.

Intervention studies are still maturing. A small randomized trial (the TRIIM trial) reported that a combination of growth hormone, DHEA, and metformin reversed epigenetic age by approximately 2.5 years over one year of treatment, though the study had significant limitations including small sample size and lack of a placebo group. Observational data consistently link physical activity, Mediterranean-style diets, and adequate sleep to slower epigenetic aging, but large, controlled trials isolating the effect of specific lifestyle factors on methylation-based biological age are still limited. The causal direction also remains an open question in many cases: whether methylation changes drive aging or merely reflect it is an active area of investigation. Animal studies, particularly those using Yamanaka factors to reprogram methylation, suggest that at least some age-related methylation changes are causally linked to functional decline, but translating these findings to humans remains speculative.

DNA methylation testing provides a snapshot that can be influenced by recent illness, medication use, and sample handling, so single measurements should be interpreted cautiously. Over-supplementation with methyl donors (particularly high-dose folic acid) may have unintended consequences: some research suggests that excess folic acid could promote the growth of pre-existing precancerous cells by providing methyl groups that support rapid DNA synthesis. Individuals with certain cancers or pre-cancerous conditions should discuss methyl donor supplementation with a clinician. MTHFR variant status, while relevant to folate metabolism, has been over-commercialized, and many claimed associations lack strong supporting evidence. The clinical utility of epigenetic age tests is still developing; acting on results without understanding their limitations can lead to unnecessary anxiety or unvalidated interventions.